Navigation Links
Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
Date:11/8/2013

(PRWEB) November 08, 2013

Drug maker Johnson & Johnson has agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the federal government has reported that there are health risks associated with use of the drug among those groups.

The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega, according to a Nov. 4 New York Times story.* The federal government alleges J&J marketed the drug to high-risk groups between 1999 and 2005, the story said, adding that part of the settlement includes J&J pleading guilty to a criminal misdemeanor for its role in promoting the drug to those groups (United States of America v. Janssen Pharmaceuticals, Inc.; 13-605; U.S. District Court for the Eastern District of Pennsylvania).

Risperdal has been shown to nearly double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

“Unfortunately, that $2.2 billion represents criminal and civil fines, not money to compensate victims,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Those injured by Johnson & Johnson’s actions should consider retaining an attorney to assist them in seeking to obtain compensation for harms allegedly suffered from use of the drug."

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn more about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/risperdal-lawsuits/heart-failure/prweb11315249.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
2. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
3. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
4. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
5. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
6. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
7. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
8. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
9. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Orders in Federal Litigations for Ethicon, American Medical Systems Lawsuits
10. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Hearing Scheduled on Remand of Stryker Hip Recall Claim to State Court
11. A Consumer Class Action Lawsuit Has Been Filed Over Allegedly Deceptive “Novarel Slim iPant,” “Flexees” Fat Destruction and Cellulite Slimming Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... , ... Gym Source, America’s leading retailer of premium residential and commercial fitness ... Miami, FL. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help ... Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. Bernie ... pass through tough times, Dr. Bernie Siegel energizes listeners to live life with ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... San Clemente, CA (PRWEB) , ... January 17, ... ... San Diego County, as well as Palm Desert, is opening a new office ... of Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017  Tarix ... Drug Administration has granted a Rare Pediatric Disease (RPD) ... treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare ... for RDEB and treatment is limited to supportive care. ... supplements the Orphan Drug Designation previously granted by the ...
(Date:1/18/2017)... Jan. 18, 2017  Robust competition in the ... discounts on medicine prices, according to a new ... study is among the first to examine the share ... manufacturers, pharmacy benefit managers (PBMs), health plans and other ... study is the first to show what happens when ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology: